Sanofi’s $1.53 Billion China Bet Signals a New Map for Biotech Innovation
The rovadicitinib deal is about more than one blood-cancer and
Amgen’s $840m wager on Dark Blue shows why pharma keeps paying to make proteins disappear
On a cold Tuesday in early January, Amgen quietly made
Obesity’s next arms race: staying power, not just weight loss
The GLP-1 era has changed what patients and investors think
The GLP-1 pill arrives: Novo’s oral Wegovy reshapes the obesity market
On December 22, 2025, the U.S. Food and Drug Administration
When the FDA Starts Trusting Algorithms: What AIM-NASH Means for Liver Drug Trials
Regulators have just qualified an AI system to score liver
The anti-ageing bet on the liver: why longevity biotech’s first real drugs may start here
A new generation of biotech start-ups is trying to “rejuvenate”
The explainable aging clock regulators might actually like
A new bioRxiv preprint introduces ACE—Aging Cell Embeddings—an explainable, deep-generative
The obesity wars go to court: Pfizer says Novo’s Metsera bid is a moat, not a merger
As the GLP-1 gold rush enters its most aggressive phase,
Galapagos quits cell therapy. Europe’s CGT reckoning begins.
Late on Monday night in California — 10:30 p.m. PT
The AI science factory arrives: why Lila’s $1.3bn valuation matters beyond biotech
Lila’s Nvidia-backed raise is about more than money. It is
Pfizer’s $4.9bn Metsera bet: can amylin finally tame GLP-1’s ‘GI tax’?
Pfizer has rejoined the weight-loss race with a $4.9bn move
From Crypto to Cytoplasm: Brian Armstrong’s NewLimit Targets Hepatocytes for Anti-Aging Breakthrough
In a biotech landscape often preoccupied with the elusive fountain
Roche’s Bold Foray into Obesity Treatment: A $5.3 Billion Bet on Petrelintide
In a strategic move poised to reshape the landscape of
AbbVie Enters Obesity Drug Market with $2.2B Gubra Licensing Deal
AbbVie, a leading biopharmaceutical company, has taken a significant step
Metsera’s Weight-Loss Drug MET-097i Shows Strong Clinical Results
Obesity remains a critical public health challenge in the United
Pharma Giant Eli Lilly to Buy Biotech Firm Morphic for $3.2 Billion
Eli Lilly and Company, a global leader in pharmaceutical development,
UroGen Aims to Raise $107M to Advance Innovative Obesity and Bladder Cancer Therapies
Introduction Overview of UroGen: UroGen Pharma Ltd., headquartered in Princeton,
MOST POPULAR
